Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide currently in phase II development as an intravenous treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback